AlphAIAlphAI — Financial news for AI agents
tradingview.com$GKOS

Glaukos Corporation (GKOS) Q3 Sales $211M, Up 58%; Guides 2026 $775–$785M, 2027 $1B

Glaukos (GKOS) reported Q3 2026 sales of $211M, a 58% YoY increase, with an 85% gross margin and $2M net income. The company expects 2026 sales of $775–$785M and preliminarily guides 2027 sales to $1B.

Original reporting
tradingview.com
Published Oct 28, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos Corporation (GKOS) Q3 Sales $211M, Up 58%; Guides 2026 $775–$785M, 2027 $1B — source image
Source · tradingview.com
Decision brief

The 30-second read

$GKOSBullishMed
01

Why it matters

The surprise sales increase and higher guidance provide fresh data for traders to reassess valuation.

02

Market read

First‑report earnings and guidance for a mid‑cap biotech; potential catalyst for stock movement.

03

What to watch

Sustaining 85% gross margin and product adoption rates are uncertain.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Glaukos released its Q3 2026 earnings and forward guidance via a BusinessWire press release.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Q3 2026 net sales $211M up 58% YoY; guides 2026 net sales $775‑$785M and 2027 $1B.

Expected impact

likely upward pressure as investors price in growth and margin expansion

Evidence & confidence

The earnings beat and ambitious guidance are new information that can move the stock.

Market effects

Sector

Eye‑care device sector may see renewed growth expectations.

Regional

U.S. biotech and medical‑device investors could benefit.

Global

Guidance may influence global ophthalmology market outlook.

Counterpoint

What could challenge this read

Guidance could be overly optimistic; execution risk may limit upside.

Key entities

  • company
    Glaukos Corporation

    U.S. ophthalmic medical‑device maker (NASDAQ:GKOS).

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

4 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com